2399. PLGF (Placental Growth Factor. Marker of preeclampsia)_ Roche
Description
PLGF is a sensitive marker of placentation disorders. When combined with other indicators, it helps in the early detection of preeclampsia risk and the determination of further pregnancy management. Recommended in the first through third trimesters.
When and who needs the test?
In the first trimester (11 weeks – 13 weeks + 6 days):
- for individualized calculation of the risk of preeclampsia (PE) using the FMF algorithm in the ASTRAIA program;
- as part of a combined preeclampsia screening, including:
- PLGF, MAP (mean arterial pressure), PAPP-A, CRL, and uterine artery Doppler ultrasound;
- for timely administration of acetylsalicylic acid prophylaxis in high-risk patients.
In the second and third trimesters (up to 37 weeks):
- for arterial hypertension, intrauterine growth restriction (IUGR);
- for borderline or questionable Doppler ultrasound results;
- in cases of high risk of PE based on medical history or biomarkers;
- for dynamic monitoring of pregnant women with established preeclampsia;
- in combination with the determination of the PlGF/sFlt-1 ratio, which allows for a more precise diagnosis, assessment of the severity of the disorder and prognosis.
Biological material
- Venous blood
Preparing for a blood test
In order to exclude factors that may affect the test results, we recommend to follow the preparation rules:
- an important condition for laboratory tests is to take blood on an empty stomach.
- 6-12 hours before the test, you should avoid eating, drinking alcohol, smoking, and limit physical activity. Drinking...
Cheaper in a package